EBM is often quotes as a scientific basis for medical interventions and policy making. Its foundation is to systematically review information arising from Randomized Clinical Trials (RCTs) and meta-analysis. In its present status, it should be applied cautiously in the context of developing countries. This is due to two reasons: Firstly, many RCTs are often conducted in Europe or North America. This ignores the issue of racial differences in therapeutic responses, which are well documented. Thus survival rates, morbidity figures are not directly applicable across racial boundaries. Extrapolating from European and North America studies to different racial groups in developing countries is likely to be even less reliable, when we add the geographical and cultural differences between continents. Secondly, quality of life measures, used in some of the studies, have been developed in Europe or North America In many instances researchers or academics developed these indices based on their perceptions of health and illness. Since these indices are value based and therefore culture sensitive, their use across continents and countries is questionable. The medical profession and policy planners in developing countries should take the above into consideration when using available Evidence Based information, (RCTs and meta-analysis) for their countries.